AstraZeneca shares rise as China probe update reassures
AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over ...
TD Cowen Reaffirms Their Buy Rating on AstraZeneca (AZN)
TD Cowen analyst Steve Scala maintained a Buy rating on AstraZeneca (AZN – Research Report) today. The company’s shares closed yesterday at ...
AstraZeneca reports Q4 core EPS $2.09
Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total Revenue ...
Seeking Alpha on MSN10h
AstraZeneca outlines $3.2 dividend hike and anticipates strong 2025 growth
Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...
STAT14h
AstraZeneca offers some reassurance on China challenges
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...